Anti-Chromogranin B CHGB Monoclonal Antibody

Overview

This product is an anti-CHGB antibody for target detection and characterization. Key identifiers include host species: Rabbit; Monoclonal; clone ACFG-3; isotype Rabbit IgG; reactivity: Human,Mouse,Rat. Reported application contexts include WB (as provided in the source record). Boster Bio Anti-Chromogranin B CHGB Monoclonal Antibody catalog # M04073. Tested in WB application. This antibody reacts with Human, Mouse, Rat.

Key elements and design rationale

• Target: CHGB (Serine/threonine-protein kinase N2).
• Antibody format: Monoclonal; clone ACFG-3; isotype Rabbit IgG.
• Host: Rabbit.
• Species reactivity: Human,Mouse,Rat (confirm in your model system with appropriate controls).

This description is intended to help interpret the antibody design and the biological context of the target using the fields provided in the catalog record, alongside general experimental considerations.

Biological background

CHGB (protein: T-cell surface glycoprotein CD3 zeta chain) is a commonly studied target in molecular and cellular biology. Functional context (as provided): PKC-related serine/threonine-protein kinase and Rho/Rac effector protein that participates in specific signal transduction responses in the cell. Plays a role in the regulation of cell cycle progression, actin cytoskeleton assembly, cell migration, cell adhesion, tumor cell invasion and transcription activation signaling processes. Phosphorylates CTTN in hyaluronan-induced astrocytes and hence decreases CTTN ability to associate with filamentous actin. Phosphorylates HDAC5, therefore lead to impair HDAC5 import. RhoA target required for the regulation of the maturation of primordial junctions into apical junction formation in bronchial epithelial cells. Required for G2/M phases of the cell cycle progression and abscission during cytokinesis in a ECT2-dependent manner. Stimulates FYN kinase activity that is required for establishment of skin cell-cell adhesion during keratinocytes differentiation. Regulates epithelial bladder cells speed and ion of movement during cell migration and tumor cell invasion. Inhibits Akt pro-survival-induced kinase activity. Mediates Rho protein-induced transcriptional activation via the c- fos serum response factor (SRF). Phosphorylates HCV NS5B leading to stimulation of HCV RNA replication. . Reported cellular localization context: Cytoplasm . Nucleus . Membrane . Cell projection, lamellipodium . Cytoplasm, cytoskeleton . Cleavage furrow . Midbody . Cell junction . Colocalizes with PTPN13 in lamellipodia-like structures, regions of large actin turnover. Accumulates during telophase at the cleavage furrow and concentrates finally around the midbody in cytokinesis. Recruited to nascent cell-cell contacts at the apical surface of cells. In the course of viral infection, colocalizes with HCV NS5B at perinuclear region in the cytoplasm. . Tissue expression notes (as provided): Ubiquitous. Expressed in numerous tumor cell lines, especially in bladder tumor cells. .

Research relevance and current trends

• Research context keywords from the source record include: Growth Factors/Hormones,Neurology Process,Neuroscience,Signal Transduction.
• Current studies often focus on connecting target abundance/localization to pathway perturbations across models, tissues, and cell states.
• Quantitative and multiplexed assays (e.g., imaging + immunoblot panels) are commonly used to compare phenotypes across conditions and time-courses.

Common research applications

• Western blotting (WB): assess relative target abundance across samples, treatments, or time-points.

Workflow ideas (metafield): Validate CHGB antibody specificity using KO/KD control samples (WB/IF/IHC as appropriate), Detect CHGB expression by Western blot in cell or tissue lysates, Compare relative CHGB levels across experimental conditions (dose/time-course) using antibody-based readouts

Notes for experimental interpretation

• Consider isoforms and post-translational modifications (PTMs) that may shift apparent molecular weight or epitope accessibility.
• Apparent molecular weight may vary by sample type and processing (observed MW: 190 kDa; calculated MW: 112035 MW).
• Control concepts: include appropriate negative controls (e.g., isotype, KO/KD samples) and orthogonal validation when feasible.

Additional product details (from the source record)

• Molecular weight (observed): 190 kDa
• Cellular localization (provided): Cytoplasm . Nucleus . Membrane . Cell projection, lamellipodium . Cytoplasm, cytoskeleton . Cleavage furrow . Midbody . Cell junction . Colocalizes with PTPN13 in lamellipodia-like structures, regions of large actin turnover. Accumulates during telophase at the cleavage furrow and concentrates finally around the midbody in cytokinesis. Recruited to nascent cell-cell contacts at the apical surface of cells. In the course of viral infection, colocalizes with HCV NS5B at perinuclear region in the cytoplasm. .
• Tissue details (provided): Ubiquitous. Expressed in numerous tumor cell lines, especially in bladder tumor cells. .

Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.